
Napa Parinyanitikul

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8953108/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Lactic acidosis, a potential toxicity from drug–drug interaction related to concomitant ribociclib and metformin in preexisting renal insufficiency: A case report. Cancer Reports, 2022, 5, e1575.	1.4	5
2	Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy. JCO Precision Oncology, 2022, 6, e2000368.	3.0	9
3	An open-label, randomized, controlled trial to evaluate the efficacy of antihistamine premedication and infusion prolongation in prevention of hypersensitivity reaction to oxaliplatin Journal of Clinical Oncology, 2022, 40, 12099-12099.	1.6	0
4	Safety and efficacy of YBL-006, an anti-PD-1 monoclonal antibody in advanced solid tumors: A phase I study Journal of Clinical Oncology, 2022, 40, e14557-e14557.	1.6	0
5	Optimizing outcomes for patients with metastatic prostate cancer: insights from South East Asia Expert Panel. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592098546.	3.2	1
6	What is the best systemic treatment for newly diagnosed inflammatory breast cancer?—a narrative review. Chinese Clinical Oncology, 2021, 10, 55-55.	1.2	1
7	Rate of complete chemotherapy as planned with comprehensive geriatric assessment guided intervention among vulnerable elderly cancer patients: A randomized-open-label study Journal of Clinical Oncology, 2020, 38, e24021-e24021.	1.6	Ο
8	Tumor mutational profile of triple negative breast cancer patients in Thailand revealed distinctive genetic alteration in chromatin remodeling gene. PeerJ, 2019, 7, e6501.	2.0	18
9	Cooperative Effect of Oncogenic <i>MET</i> and <i>PIK3CA</i> in an HGF-Dominant Environment in Breast Cancer. Molecular Cancer Therapeutics, 2019, 18, 399-412.	4.1	9
10	Prognostic significance of cyclin B1 expression plus clinicopathologic features in hormonal positive, HER2 negative early breast cancer in King Chulalongkorn Memorial Hospital During 2010-2015 Journal of Global Oncology, 2019, 5, 75-75.	0.5	0
11	Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy. Supportive Care in Cancer, 2018, 26, 2471-2477.	2.2	12
12	A phase 2 study of s-1 plus leucovorin in patients with untreated advanced cholangiocarcinoma (CCA) Journal of Clinical Oncology, 2018, 36, 467-467.	1.6	0
13	Molecular subtypes of triple-negative breast cancer (TNBC) tumor samples obtained before and after neoadjuvant systemic therapy (NST) and relationship between immunomodulatory (IM) gene signature and intensity of tumor-infiltrating lymphocytes (TILs) Journal of Clinical Oncology, 2018, 36, 12069-12069.	1.6	Ο
14	Efficacy and safety of additional olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting: A randomized, double-blind, placebo-controlled, crossover study Journal of Clinical Oncology, 2018, 36, 10019-10019.	1.6	0
15	Feasibility of withholding dexamethasone premedication for hypersensitivity reactions associated with paclitaxel administration. Asian Biomedicine, 2017, 10, 371-377.	0.3	3
16	Feasibility of withholding dexamethasone premedication in patients not experiencing two previous cycles of weekly paclitaxel related infusion hypersensitivity reaction Journal of Clinical Oncology, 2016, 34, e21634-e21634.	1.6	1
17	The cost-effectiveness analysis of EGFR mutation test for management of advanced non-small cell lung cancer in Thailand Journal of Clinical Oncology, 2016, 34, e20636-e20636.	1.6	0
18	The accuracy of carboplatin area under the curve (AUC) estimated by Calvert formula using Cockcroft-Gault formula and Thai eGFR in Thai cancer patients Journal of Clinical Oncology, 2016, 34, e14017-e14017.	1.6	0

NAPA PARINYANITIKUL

#	Article	IF	CITATIONS
19	Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes. Clinical Breast Cancer, 2015, 15, 153-160.	2.4	33
20	Functional consequence of the <i>MET-T</i> 1010I polymorphism in breast cancer. Oncotarget, 2015, 6, 2604-2614.	1.8	34
21	cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. Journal of Cancer, 2014, 5, 745-753.	2.5	46
22	Prevalence of KRAS gene mutation in ampullary cancer in Thai patients Journal of Clinical Oncology, 2014, 32, e15175-e15175.	1.6	2
23	Analysis of KRT14 and SFTPB expression by immunohistochemistry method in squamous cell carcinoma of lung and head-neck cancer tissue Journal of Clinical Oncology, 2014, 32, e22127-e22127.	1.6	0
24	Effect of adjuvant trastuzumab (T) among patients treated with neoadjuvant T-based chemotherapy Journal of Clinical Oncology, 2014, 32, 644-644.	1.6	0
25	Mesothelin Expression and Survival Outcomes inÂTriple Receptor Negative Breast Cancer. Clinical Breast Cancer, 2013, 13, 378-384.	2.4	32
26	Disparities in Access to Systemic Treatment for Breast Cancer in Thailand and Major Asian Territories. Journal of Breast Cancer, 0, 25, .	1.9	2